COMMUNIQUÉS West-GlobeNewswire

Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
30/06/2025
Long-term efficacy and safety data on PALSONIFY TM (paltusotine) in acromegaly to be presented, including evidence of both biochemical and symptom control with a well-tolerated safety profile in patients switching [...]
Dyne Therapeutics Announces Proposed Public Offering of Common Stock
30/06/2025
WALTHAM, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular [...]
INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
30/06/2025
Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct [...]
PetVivo Reports Fiscal 2025 Results
30/06/2025
MINNEAPOLIS, MN, US, June 30, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. and its wholly-owned subsidiary PetVivo Animal Health, Inc. (OTCQB: PETV; OTCPINK: PETVW), a leading biomedical company delivering innovative [...]
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30/06/2025
BOSTON, June 30, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation antibody-drug conjugate (‘ADC’) therapeutics for difficult-to-treat cancers, reported [...]
Aptose Announces Deferral of Interest Payment
30/06/2025
SAN DIEGO and TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple [...]
TerrAscend Announces Strategic Exit from Michigan Market
30/06/2025
Net Proceeds from divestitures to pay down Company debt Enables concentrated growth and improved profitability in core markets TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. (“TerrAscend”) (TSX: TSND, OTCQX [...]
Academy Announces Host, Executive Producer and Author Andy Cohen as 2025 FNCE® Closing Keynote Speaker
30/06/2025
CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Food and nutrition experts from around the world will gather in Nashville, Tenn., October 11-14, for the Academy of Nutrition and Dietetics' 2025 Food & Nutrition [...]
Algernon Announces Amended Terms for Private Placement and Closing of the First Tranche totaling $621,000
30/06/2025
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: [...]
Avicanna Announces Results of Annual General Meeting
30/06/2025
TORONTO, June 30, 2025 (GLOBE NEWSWIRE) -- Avicanna Inc. (“ Avicanna ” or the “ Company ) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and [...]
Thought Leadership & Innovation Foundation Releases White Paper Showcasing Model for Non-Profit Collaboration to Improve Outcomes for Chronic Disease Communities
30/06/2025
MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI), a nonprofit at the forefront of health innovation, today announced the release of a groundbreaking white paper, A [...]
Total number of shares and voting rights in Zealand Pharma as of June 30, 2025
30/06/2025
Company announcement – No. 16 / 2025 Total number of shares and voting rights in Zealand Pharma as of June 30, 2025 Copenhagen, Denmark, June 30, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
30/06/2025
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension – – Lorundrostat 50 mg once daily demonstrated clinically [...]
Portal Biotech Raises $35 Million Series A, Leveraging AI to Deliver the World’s First Full-Length Single-Molecule Protein Sequencer
30/06/2025
Breakthrough proteomics platform technology unlocks full-length protein sequencing and characterisation, accelerating drug development and diagnostics LONDON, June 30, 2025 (GLOBE NEWSWIRE) -- Portal Biotech, a [...]
Erdem Hospital Launches New Pre-Surgery Education Program for Bariatric Patients
30/06/2025
Photo: Erdem Hospital via FL Communications ISTANBUL, June 30, 2025 (GLOBE NEWSWIRE) -- Erdem Hospital in Istanbul has announced the launch of a new pre-operative education program tailored specifically for bariatric [...]
EUROAPI cède le site de Haverhill à Particle Dynamics dans le cadre du plan de transformation FOCUS-27
30/06/2025
Communiqué de presse Paris – Le 30 juin 2025 - EUROAPI annonce ce jour la signature d’un accord (Share Purchase Agreement - SPA) portant sur la cession de 100% des titres de EUROAPI UK Ltd, la filiale exploitant son [...]
EUROAPI sells Haverhill site to Particle Dynamics as part of its FOCUS-27 transformation plan
30/06/2025
Press Release Paris – June 30, 2025 – EUROAPI today announced the signing of a share purchase agreement (SPA) for the sale of 100% of EUROAPI UK Ltd, the subsidiary operating its Haverhill manufacturing site, with a [...]
OSE Immunotherapeutics publie une Lettre aux Actionnaires
30/06/2025
OSE Immunotherapeutics publie une Lettre aux Actionnaires NANTES, France, 30 juin 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), annonce la publication de sa première Lettre aux [...]
OSE Immunotherapeutics Publishes Letter to Shareholders
30/06/2025
OSE Immunotherapeutics Publishes Letter to Shareholders NANTES, France, June 30, 2025, 6:00 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), announces the publication of its inaugural Letter to [...]

Pages